Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-epirubicin in patients with breast cancer.

Yang Q, Wang XD, Chen J, Tian CX, Li HJ, Chen YJ, Lv Q.

Tumour Biol. 2012 Dec;33(6):2341-8. doi: 10.1007/s13277-012-0496-y. Epub 2012 Sep 5.

PMID:
22948779
2.

Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.

Du J, Zhang Y, Ming J, Liu J, Zhong L, Liang Q, Fan L, Jiang J.

World J Surg Oncol. 2016 Jun 22;14(1):164. doi: 10.1186/s12957-016-0925-2.

3.

[Impact of preoperative lymphatic chemotherapy on relapse and metastasis of breast cancer and its mechanism].

Wu WJ, Zeng J, Lu YF, Jiang WZ, Chen L, Pan CE.

Ai Zheng. 2005 Dec;24(12):1537-41. Chinese.

PMID:
16351809
4.

[Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis].

Wu WJ, Zeng J, Pan CE.

Nan Fang Yi Ke Da Xue Xue Bao. 2006 Dec;26(12):1812-4. Chinese.

5.

[Effect of preoperative lymphatic chemotherapy on Bcl-2 and Bax expression in axillary metastasis of breast cancer].

Wu WJ, Pan CE, Zeng J.

Di Yi Jun Yi Da Xue Xue Bao. 2005 Aug;25(8):1001-4. Chinese.

6.

[Drug concentration in axillary lymph nodes of patients with breast cancer after lymphatic chemotherapy].

Chen JH, Yang YM, Li KZ, Ling R, Yao Q, Yang H.

Ai Zheng. 2005 Apr;24(4):494-7. Chinese.

PMID:
15820077
7.

Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer.

Chen J, Wang L, Yao Q, Ling R, Li K, Wang H.

Breast Cancer Res. 2004;6(4):R474-7. Epub 2004 Jun 17.

8.

Lymphatic chemotherapy induces apoptosis in lymph node metastases in a rabbit breast carcinoma model.

Ling R, Li Y, Yao Q, Chen T, Zhu D, Jun Y, Chen J.

J Drug Target. 2005 Feb;13(2):137-42.

PMID:
15823965
9.

Colorectal cancer lymph node staining by activated carbon nanoparticles suspension in vivo or methylene blue in vitro.

Cai HK, He HF, Tian W, Zhou MQ, Hu Y, Deng YC.

World J Gastroenterol. 2012 Nov 14;18(42):6148-54. doi: 10.3748/wjg.v18.i42.6148.

10.
11.

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.

Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M.

Ann Oncol. 2007 Jan;18(1):52-7. Epub 2006 Oct 17.

PMID:
17047001
12.

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart M, de Azambuja E, Loi S.

Breast. 2014 Aug;23(4):473-81. doi: 10.1016/j.breast.2014.03.012. Epub 2014 Apr 24.

PMID:
24768477
13.

Lymphatic-targeted therapy following neoadjuvant chemotherapy: a promising strategy for lymph node-positive breast cancer treatment.

Chen J, Yao Q, Wang H, Wang B, Zhang J, Wang T, Lv Y, Han Z, Wang L.

Med Oncol. 2015 Jul;32(7):184. doi: 10.1007/s12032-015-0634-7. Epub 2015 May 26.

PMID:
26008153
14.

Effect of preoperative injection of carbon nanoparticle suspension on the outcomes of selected patients with mid-low rectal cancer.

Zhang XM, Liang JW, Wang Z, Kou JT, Zhou ZX.

Chin J Cancer. 2016 Apr 4;35:33. doi: 10.1186/s40880-016-0097-z.

15.

[Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].

Zang MF, Zhang YM, Zhi YH, Zhai Z, Zhang M, Gu F, Zhi XC.

Zhonghua Yi Xue Za Zhi. 2011 May 31;91(20):1388-92. Chinese.

PMID:
21756809
16.

[Studies on the lymphatic tropism and lymph cells apoptosis of cisplatin-nano carbon suspension in the rats].

Hou M, Chen Z, Li L, Wang P, Qie M.

Zhonghua Fu Chan Ke Za Zhi. 2014 Nov;49(11):847-51. Chinese.

PMID:
25603911
17.

Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study.

Fountzilas G, Nicolaides C, Aravantinos G, Skarlos D, Kosmidis P, Papakostas P, Stathopoulos GP, Kontostolis E, Bafaloukos D, Pavlidis N.

Oncology. 1998 Nov-Dec;55(6):508-12.

PMID:
9778614
18.

Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.

Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA.

Am J Surg Pathol. 2000 Sep;24(9):1266-72.

PMID:
10976701
19.

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.

Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK.

Breast Cancer Res Treat. 2005 Jul;92(1):69-75.

PMID:
15980993
20.

[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].

Li Q, Xu BH, Zhang P, Li Q, Yuan P, Wang JY, Luo Y, Ma F, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):207-11. doi: 10.3760/cma.j.issn.0253-3766.2013.03.010. Chinese.

PMID:
23880002

Supplemental Content

Support Center